A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease

被引：10
|
作者：
Faridar, Alireza [1 ]
Eid, Abdulmunaim M. [1 ]
Thome, Aaron D. [1 ]
Zhao, Weihua [1 ]
Beers, David R. [1 ]
Pascual, Maria B. [1 ]
Nakawah, Mohammad O. [1 ]
Roman, Gustavo C. [1 ]
Davis, Charles S. [2 ]
Grundman, Michael [3 ,4 ]
Masdeu, Joseph C. [1 ]
Appel, Stanley H. [1 ]
机构：
[1] Houston Methodist Res Inst, Stanley H Appel Dept Neurol, 6565 Fannin St,Suite P3-201, Houston, TX 77030 USA
[2] CSD Biostat Inc, Oro Valley, AZ USA
[3] Global R&D Partners LLC, San Diego, CA USA
[4] Univ Calif San Diego, San Diego, CA USA
来源：
TRANSLATIONAL NEURODEGENERATION | 2023年 / 12卷 / 01期
关键词：
D O I：
10.1186/s40035-023-00387-5
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Trial registrationClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
    Alireza Faridar
    Abdulmunaim M. Eid
    Aaron D. Thome
    Weihua Zhao
    David R. Beers
    Maria B. Pascual
    Mohammad O. Nakawah
    Gustavo C. Roman
    Charles S. Davis
    Michael Grundman
    Joseph C. Masdeu
    Stanley H. Appel
    Translational Neurodegeneration, 12
  • [2] An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
    Vasiliauskas, EA
    Kam, LY
    Abreu-Martin, MT
    Hassard, PV
    Papadakis, KA
    Yang, HY
    Zeldis, JB
    Targan, SR
    GASTROENTEROLOGY, 1999, 117 (06) : 1278 - 1287
  • [3] Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma
    Miyake, Hideaki
    Kurahashi, Toshifumi
    Takenaka, Atsushi
    Inoue, Taka-aki
    Fujisawa, Masato
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (06) : 598 - 603
  • [4] Low-dose dengue virus 3 human challenge model: a phase 1 open-label study
    Waickman, Adam T.
    Newell, Krista
    Lu, Joseph Q.
    Fang, Hengsheng
    Waldran, Mitchell
    Gebo, Chad
    Currier, Jeffrey R.
    Friberg, Heather
    Jarman, Richard G.
    Klick, Michelle D.
    Ware, Lisa A.
    Endy, Timothy P.
    Thomas, Stephen J.
    NATURE MICROBIOLOGY, 2024, 9 (05) : 1356 - 1367
  • [5] Low-dose dengue virus 3 human challenge model: a phase 1 open-label study
    Adam T. Waickman
    Krista Newell
    Joseph Q. Lu
    HengSheng Fang
    Mitchell Waldran
    Chad Gebo
    Jeffrey R. Currier
    Heather Friberg
    Richard G. Jarman
    Michelle D. Klick
    Lisa A. Ware
    Timothy P. Endy
    Stephen J. Thomas
    Nature Microbiology, 2024, 9 : 1356 - 1367
  • [6] An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer's Disease
    Gordon, Marc L.
    Christen, Erica
    Keehlisen, Lynda
    Gong, Michelle
    Lam, Fung
    Giliberto, Luca
    Gomar, Jesus J.
    Koppel, Jeremy
    JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2024, 8 (01) : 1111 - 1114
  • [7] Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study
    Eisenchlas, JH
    Garrigue, N
    Junin, M
    De Simone, GG
    PALLIATIVE MEDICINE, 2005, 19 (01) : 71 - 75
  • [8] Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
    Altman, Robert D.
    Lang, Anthony E.
    Postuma, Ronald B.
    MOVEMENT DISORDERS, 2011, 26 (13) : 2427 - 2431
  • [9] An open-label pilot study with high-dose thiamine in Parkinson's disease
    Antonio Costantini
    Roberto Fancellu
    Neural Regeneration Research, 2016, (03) : 406 - 407
  • [10] An open-label pilot study with high-dose thiamine in Parkinson's disease
    Costantini, Antonio
    Fancellu, Roberto
    NEURAL REGENERATION RESEARCH, 2016, 11 (03) : 406 - 407
12345